vimarsana.com

Germany's Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor. Read more at straitstimes.com.

Related Keywords

Xia Fxia ,Data Monitoring Committee ,Reuters ,Independent Data Monitoring Committee ,

© 2025 Vimarsana

vimarsana.com © 2020. All Rights Reserved.